Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRV 027

Next Previous
Drug Profile

TRV 027

Alternative Names: Beta-arrestin biased ligand - Trevena; MPS-418; TRV-120027; TRV027; β-arrestin biased ligand - Trevena

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trevena
  • Developer Imperial College of Science, Technology and Medicine; National Heart, Lung and Blood Institute; Trevena
  • Class Heart failure therapies; Oligopeptides; Vasodilators
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Beta-arrestin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • No development reported Blood coagulation disorders; SARS-CoV-2 acute respiratory disease
  • Discontinued Acute heart failure

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for preclinical development in SARS-COV-2 acute respiratory disease in USA
  • 05 Feb 2024 Vanderbilt University Medical Center completes the phase II/III NECTAR trial in COVID-2019 infections in USA (IV) (NCT04924660)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Blood-coagulation-disorders in United Kingdom (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top